RxDoctor Payments Data

Alexander Hardwick, MD

Cardiovascular Disease · Santa Barbara, CANPI 1780050385

Payments from drug & device makers

$1,901in general payments, 2019–2025

Across 88 payments — averaging $21.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$379
  • Amgen$203
  • AstraZeneca$177
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$133
  • Boehringer Ingelheim$129
  • Johnson & Johnson$118
  • plus $763 from 16 others

What the payments were for

  • Food & beverage$1,901100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,901 in reported general payments places this provider in the 45th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$525,297
Medicare patients
1,651
Services billed
6,454

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban294$420,882
VyndamaxTafamidis13$290,476
VyndaqelTafamidis Meglumine12$268,066
XareltoRivaroxaban120$174,691
JardianceEmpagliflozin91$119,457
FarxigaDapagliflozin Propanediol46$61,546
EntrestoSacubitril/Valsartan41$60,962
Repatha SureclickEvolocumab56$56,849
Repatha PushtronexEvolocumab18$17,958
Praluent PenAlirocumab25$12,409
Metoprolol Succinate363$5,605
Dofetilide13$4,897
Atorvastatin Calcium383$3,752
Dabigatran EtexilateDabigatran Etexilate Mesylate23$3,669
Flecainide Acetate35$3,538

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax, Vyndaqel$22$979,424319 claims
Johnson & JohnsonXarelto$118$174,691120 claims
Boehringer IngelheimJardiance$129$119,45791 claims
AstraZenecaFarxiga$177$61,54646 claims
NovartisEntresto$379$60,96241 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →